阿立哌唑对抑郁症患者的疗效及相关因子水平的影响

Abstract
Figure/Table
References (29)
Related Citation (15)

Download: PDF (576 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of Aripiprazole in the treatment of depression and its effect on related factors. Methods A total of 300 patients with depression diagnosed in the Eighth Hospital of Shijiazhuang City, Hebei Province from July 2015 to March 2019 were selected and divided into study group and control group according to random number table method, with 150 patients in each group. All patients did not respond well to selective serotonin reuptake inhibitors (SSRIs). The study group was treated with Venfarazine + Aripiprazole, while the control group was treated with Venfarazine + placebo. The two groups were treated for twelve weeks. Results Overall analysis showed that there were significant differences in the Hamilton depression scale (HAMD-21) between the two groups in comparison between groups, time point comparison and interaction (all P ＜ 0.05). Comparison within the two groups: HAMD-21 scores of the two groups were compared at each time point, and the differences were statistically significant (all P ＜ 0.05). Comparison between groups: After four, eight and twelve weeks of treatment, the HAMD-21 scores in the study group were lower than those in the control group, and the differences were statistically significant (all P ＜ 0.05). After twelve weeks of treatment, serum levels of 5-hydroxytryptamine, norepinephrine and dopamine in both groups were higher than before treatment, and those in the study group were higher than those in the control group, and the differences were statistically significant (all P < 0.05). After twelve weeks of treatment, the overall distribution of clinical efficacy in the study group was better than that in the control group, and the difference was statistically significant (P ＜ 0.05). During the treatment, there was no significant difference in the incidence of headache, nausea, insomnia, sweating and weight gain between the two groups (P > 0.05). Conclusion The effect of Venfarazine + Aripiprazole in the treatment of depression is better than Venfarazine alone, and its mechanism of action may be related to better regulation of related neurotransmitters.

Key words： Aripiprazole Depression Venfarazine 5-hydroxytryptamine Dopamine Norepinephrine

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Yali ZHENG Hongwei LI Weicai

Cite this article:

ZHANG Yali ZHENG Hongwei LI Weicai. Effects of Aripiprazole on the efficacy and related factors in patients with depression[J]. 中国医药导报, 2021, 18(7): 104-107.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2021/V18/I7/104

[1] 斯日古楞，刘相辰，杨帆，等.5-羟色胺1A/2A受体基因多态性与SSRIs抗抑郁疗效的相关性研究[J].中国药房，2018，29（17）：96-100.
[2] 杨洁，王刚.新型5-羟色胺再摄取抑制剂的抗抑郁治疗：多受体效应与临床作用[J].中华精神科杂志，2018，51（2）：145-148.
[3] 张少霞，郑玉玲，翁薇洁，等.喹硫平、阿立哌唑联合文拉法辛治疗难治性抑郁症的效果分析[J].中国实用医药，2018，13（21）：148-150.
[4] 万齐根，魏波，占瑾琼，等.阿立哌唑对精神分裂症患者临床症状及血清神经营养因子水平的影响[J].中国神经精神疾病杂志，2018，44（4）：217-221.
[5] 刘兰英，骆利元，朱春青，等.文拉法辛防治不同中医证型重性抑郁障碍效果评价[J].浙江预防医学，2018，30（5）：459-462.
[6] 罗小年.对《中国精神障碍分类与诊断标准，第3版》（CCMD—3）的讨论（四）——CCMD—3在编写中存在的问题[J].临床精神医学杂志，2003，13（2）：103-104.
[7] 江开达.抑郁障碍防治指南[M].北京：北京大学医学出版社，2007：62-64.
[8] Navarro V，Boulahfa I，Obach A，et al. Switching to Imipramine Versus Add-on Mirtazapine in Venlafaxine-Resistant Major Depression：A 10-Week Randomized Open Study [J]. J Clin Psychopharmacol，2018，39（1）：63-66.
[9] 陈远岭，刘小彩，唐伟，等.阿立哌唑联合抗抑郁药治疗对起始抗抑郁药无效的抑郁症患者的疗效观察[J].中国医师杂志，2018，20（4）：579-581.
[10] Sipahi H，Kad?覦o■lu B，Bayram FE?魻. Discovery of New Medication for the Treatment of Depression Comorbid with Inflammatory Diseases [J]. Curr Top Med Chem，2018，18（16）：1393-1394.
[11] Lozupone M，La Montagna M，D'Urso F，et al. Pharmacotherapy for the treatment of depression in patients with alzheimer’s disease：a treatment-resistant depressive disorder [J]. Expert Opin Pharmacother，2018，19（8）：823-842.
[12] 王科平，邢文静，韩宇扬.阿立哌唑联合草酸艾司西酞普兰在重度抑郁症治疗中的应用分析[J].川北医学院学报，2020，35（1）：42-44.
[13] 孙庆芳，王亚平.阿立哌唑联合度洛西汀治疗抑郁症的临床研究[J].现代药物与临床，2020，35（4）：712-716.
[14] 吴文波，秦承花，李燕芳.阿立哌唑治疗难治性精神分裂症的可行性及安全性分析[J].中国医药科学，2019，9（8）：61-64.
[15] 周中华.阿立哌唑治疗精神分裂症后抑郁症状的疗效观察[J].湖北科技学院学报：医学版，2019，33（5）：392-393.
[16] 高帅，陈立勇，李冠男，等.两种非典型抗精神病药物对精神分裂症患者血脂水平及不良反应的影响比较[J].中国当代医药，2019，26（22）：61-64.
[17] 段侠霞，张燕，张盟，等.非典型抗精神病药对儿童青少年精神分裂症血清甲状腺激素和血脂的影响[J].中国医药导报，2019，16（5）：157-160.
[18] Fagiolini A，Albert U，Ferrando L，et al. A randomized，double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder [J]. Int Clin Psychopharmacol，2020，35（3）：137-146.
[19] Stefani M，Roberts DM，Brett J. High-dose insulin euglycemic therapy to treat cardiomyopathy associated with massive venlafaxine overdose [J]. Clin Toxicol（Phila），2020， 58（4）：299-300.
[20] Frolkis AD，Vallerand IA，Shaheen AA，et al. Depression increases the risk of inflammatory bowel disease，which may be mitigated by the use of antidepressants in the treatment of depression [J]. Gut，2019，68（9）：1606-1612.
[21] 冀二妮，朱炼，蔡璐遥.不同剂量文拉法辛与阿戈美拉汀联合应用治疗难治性抑郁症的临床效果[J].中国当代医药，2020，27（1）：70-72.
[22] 李季，杨靖，刘安昌.度洛西汀与文拉法辛治疗老年抑郁症的疗效及对血清脑源性神经生长因子、5-羟色胺、去甲肾上腺素的影响[J].中国老年学杂志，2018，38（24）：130-132.
[23] 刘文娟，胡霖霖，宋明芬，等.中药联合文拉法辛治疗抑郁症的疗效观察[J].中国现代医生，2020，58（27）：114-117.
[24] Pranjic N，Trumic E，Bei F，et al. SSRI Antidepressant Side Effects in Depression Patients in the first 6 months of treatment [J]. Healthmed，2019，13（4）：140-147.
[25] Edvinsson ?魡，Hoyer A，Hansson M，et al. Placental glucocorticoid receptors are not affected by maternal depression or SSRI treatment [J]. Upsala J Med Sci，2020，125（1）：30-36.
[26] Lapmanee S，Charoenphandhu J，Teerapornpuntakit J，et al. Agomelatine，venlafaxine，and running exercise effectively prevent anxiety- and depression-like behaviors and memory impairment in restraint stressed rats [J]. PLoS One，2017，12（11）：e0187671.
[27] Marshe V，Maciukiewicz M，Rej S，et al. 232. Genome-Wide Association Study of Venlafaxine Treatment Remission in Late-Life Depression [J]. Biol Psychiat，2017，81（10）：S95-S96.
[28] Sharma RK，Singh T，Mishra A，et al. Relative Safety of Different Antidepressants for Treatment of Depression in Chronic Epileptic Animals Associated with Depression [J]. J Epilepsy Res，2017，7（1）：25-32.
[29] Li X，Zhu L，Su Y，et al. Short-term efficacy and tolerability of venlafaxine extended release in adults with generalized anxiety disorder without depression：A meta-analysis [J]. PLos One，2017，12（10）：e0185865.